APOE and Alzheimer disease: However, the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) trial was the first randomized controlled to evaluate the impact that disclosure of ApoE4 carrier status had on behavioral change in cognitively normal individuals and the researchers found that individuals who learned they were carriers reported more behavioral changes related to diet, exercise, medications, and vitamins compared to those who learned they were non-carriers [177].